ATE364617T1 - Fragmente des wachstumsfaktors für bindegewebe (ctgf) und verfahren und anwendungen davon - Google Patents

Fragmente des wachstumsfaktors für bindegewebe (ctgf) und verfahren und anwendungen davon

Info

Publication number
ATE364617T1
ATE364617T1 AT99965256T AT99965256T ATE364617T1 AT E364617 T1 ATE364617 T1 AT E364617T1 AT 99965256 T AT99965256 T AT 99965256T AT 99965256 T AT99965256 T AT 99965256T AT E364617 T1 ATE364617 T1 AT E364617T1
Authority
AT
Austria
Prior art keywords
ctgf
fragments
methods
applications
growth factor
Prior art date
Application number
AT99965256T
Other languages
English (en)
Inventor
Gary Grotendorst
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Application granted granted Critical
Publication of ATE364617T1 publication Critical patent/ATE364617T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
AT99965256T 1998-12-14 1999-12-14 Fragmente des wachstumsfaktors für bindegewebe (ctgf) und verfahren und anwendungen davon ATE364617T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11224098P 1998-12-14 1998-12-14
US11224198P 1998-12-14 1998-12-14

Publications (1)

Publication Number Publication Date
ATE364617T1 true ATE364617T1 (de) 2007-07-15

Family

ID=26809725

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99966224T ATE391724T1 (de) 1998-12-14 1999-12-14 FRAGMENT DES ßCONNECTIVE TISSUE GROWTH FACTORß (CTGF)
AT99965256T ATE364617T1 (de) 1998-12-14 1999-12-14 Fragmente des wachstumsfaktors für bindegewebe (ctgf) und verfahren und anwendungen davon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99966224T ATE391724T1 (de) 1998-12-14 1999-12-14 FRAGMENT DES ßCONNECTIVE TISSUE GROWTH FACTORß (CTGF)

Country Status (16)

Country Link
US (3) US6492129B1 (de)
EP (2) EP1140969B1 (de)
JP (2) JP4634614B2 (de)
KR (2) KR100664625B1 (de)
CN (3) CN1170849C (de)
AT (2) ATE391724T1 (de)
AU (3) AU773278B2 (de)
CA (2) CA2354456A1 (de)
CY (1) CY1108860T1 (de)
DE (2) DE69936315T2 (de)
DK (1) DK1140969T3 (de)
ES (2) ES2288321T3 (de)
HK (2) HK1041268B (de)
MX (1) MXPA01005949A (de)
PT (1) PT1140969E (de)
WO (2) WO2000035939A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1217067A2 (de) 1994-07-12 2002-06-26 Human Genome Sciences, Inc. Bindegewebeswachstumsfaktor-2
US7026299B2 (en) 1994-07-12 2006-04-11 Human Genome Sciences, Inc. Connective tissue growth factor-2
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
AU773278B2 (en) * 1998-12-14 2004-05-20 University Of Miami Connective tissue growth factor fragments and methods and uses thereof
CA2412124A1 (en) * 2000-07-11 2002-01-17 Haodong Li Connective tissue growth factor-2
EP1434993B1 (de) * 2001-09-18 2013-04-24 Fibrogen, Inc. Verfahren zum testen des bindegewebe-wachstumsfaktors
JP2005512976A (ja) * 2001-10-26 2005-05-12 リボファーマ アーゲー Ｒｎａ干渉により線維化疾患を処置するための医薬
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
AU2002366641A1 (en) * 2001-12-11 2003-06-23 Fibrogen, Inc. Methods for inhibiting ocular processes
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
US20050153395A1 (en) * 2003-09-29 2005-07-14 Children's Hospital Inc. Unique integrin binding site in connective tissue growth factor (CTGF)
US8258105B2 (en) 2003-10-07 2012-09-04 Isis Pharmaceuticals, Inc. Antisense oligonucleotides optimized for kidney targeting
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
GB0326778D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
ZA200607588B (en) * 2004-02-11 2008-05-28 Fibrogen Inc CTGF as target for the therapy of diabetic nephropathy
PL1715890T3 (pl) * 2004-02-11 2009-01-30 Fibrogen Inc CTGF jako cel dla terapii mikroalbinurii u pacjentów z nefropatią cukrzycową
US20050271670A1 (en) 2004-04-28 2005-12-08 Spong Suzanne M Treatments for cancer
WO2005116194A1 (ja) * 2004-05-25 2005-12-08 Riken 試験管内筋繊維形成のための筋芽細胞又は筋芽細胞様細胞培養法
EP1692935A1 (de) * 2005-02-22 2006-08-23 Boehringer Ingelheim International GmbH Transgenes Tier als Modell für Lungenkrankheiten des Menschen
JP5068253B2 (ja) 2005-05-05 2012-11-07 ファイブローゲン、インコーポレーテッド 心臓血管疾患の治療
KR101667623B1 (ko) 2005-11-30 2016-10-19 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
US20100034892A1 (en) 2006-08-30 2010-02-11 The Trustees Of Columbia University In The City Of New York Treatment for bone formation disorders by growth factor delivery
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2009061382A2 (en) * 2007-11-02 2009-05-14 Marban Eduardo T Cardiac stem cell and myocyte secreted paracrine factors and uses thereof
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
WO2010027830A2 (en) * 2008-08-25 2010-03-11 Excaliard Pharmaceuticals, Inc. Methods for modulation of connective tissue growth factor expression by administering antisense oligonucleotides through a delivery system so as to reduce scarring from wound healing and threat fibrotic diseases
CN107083386A (zh) 2008-08-25 2017-08-22 埃克斯雷德制药有限公司 阻止***生长因子的反义核苷酸及其用途
EP3336188B1 (de) 2008-09-22 2020-05-06 Phio Pharmaceuticals Corp. Selbstfreisetzende rnai-verbindungen von reduzierter grösse
CN102666587A (zh) 2009-07-02 2012-09-12 菲布罗根有限公司 用于治疗肌营养不良的方法
US20120244169A1 (en) 2009-11-06 2012-09-27 Fibrogen, Inc. Treatment for Radiation-Induced Disorders
WO2011119887A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Rna interference in dermal and fibrotic indications
EP2550001B1 (de) 2010-03-24 2019-05-22 Phio Pharmaceuticals Corp. Rna-interferenz bei augenerkrankungen
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
KR101249041B1 (ko) * 2010-04-28 2013-03-29 포항공과대학교 산학협력단 결합조직 성장인자를 이용한 약학적 조성물
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
WO2012061811A2 (en) 2010-11-05 2012-05-10 Fibrogen, Inc. Treatment method for lung remodeling diseases
WO2012100262A1 (en) 2011-01-21 2012-07-26 Fibrogen, Inc. Therapeutic method using anti - ctgf antibody
US9173894B2 (en) 2011-02-02 2015-11-03 Excaliard Pharamaceuticals, Inc. Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
WO2013094723A1 (ja) * 2011-12-22 2013-06-27 アステラス製薬株式会社 新規抗ヒトｃｔｇｆ抗体
EP2844291B1 (de) 2012-05-03 2019-02-13 Fibrogen, Inc. Verfahren zur behandlung von idiopathischer lungenfibrose
US9132171B2 (en) 2012-05-23 2015-09-15 Wisconsin Alumni Research Foundation Test of insulin as a drug to reduce restenosis of vessels
US9631013B2 (en) 2014-01-28 2017-04-25 Fibrogen, Inc. Therapeutic method for pancreatic cancer
JP2018517418A (ja) 2015-06-15 2018-07-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 情動障害の診断および治療の方法
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与***生长因子特异性结合的高亲和力核酸适配体及其应用
CN111424035A (zh) * 2020-04-13 2020-07-17 西南大学 基于家蚕丝腺表达具有生物学活性的人***生长因子的方法及其产品和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US392024A (en) * 1888-10-30 Jjett
US4906742A (en) * 1986-07-31 1990-03-06 Whitehead Institute For Biomedical Research Encoding antigens of M. Leprae
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
FR2678283A1 (fr) * 1991-06-25 1992-12-31 Centre Nat Rech Scient Sequences de nucleotides, sequences d'acides amines correspondantes, et leurs applications biologiques.
US5770209A (en) * 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5596090A (en) * 1992-07-24 1997-01-21 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human VCAM-1 RNA
EP1217067A2 (de) * 1994-07-12 2002-06-26 Human Genome Sciences, Inc. Bindegewebeswachstumsfaktor-2
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5688915A (en) 1995-06-01 1997-11-18 The University Of Medicine And Dentistry Of New Jersey Long term maintenance of lymphocytes in vitro
EP0871705A4 (de) * 1995-06-05 2000-01-26 Human Genome Sciences Inc Menschlicher ccn-ähnlicher wachstumsfaktor
EP0827742A1 (de) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Verwendung von Histondeacetylasehemmern zur Behandlung von Fibrose oder Zirrhose
US5876730A (en) * 1997-08-07 1999-03-02 Childrens Hospital Research Foundation Heparin-binding growth factor (HBGF) polypeptides
US6562618B1 (en) * 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
JP2002504332A (ja) * 1998-02-20 2002-02-12 ザイモジェネティクス，インコーポレイティド 結合組織成長因子ホモローグ
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
US6348329B1 (en) * 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
AU773278B2 (en) * 1998-12-14 2004-05-20 University Of Miami Connective tissue growth factor fragments and methods and uses thereof
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies

Also Published As

Publication number Publication date
ES2304811T3 (es) 2008-10-16
AU2004205171B2 (en) 2007-08-09
AU775391B2 (en) 2004-07-29
EP1140964A4 (de) 2003-06-18
KR20010101207A (ko) 2001-11-14
US20030180300A1 (en) 2003-09-25
JP4722290B2 (ja) 2011-07-13
US7718177B2 (en) 2010-05-18
HK1041268B (zh) 2009-02-27
ATE391724T1 (de) 2008-04-15
ES2288321T3 (es) 2008-01-01
WO2000035939A3 (en) 2000-10-12
HK1041005A1 (en) 2002-06-28
HK1041005B (zh) 2007-11-09
JP2002532084A (ja) 2002-10-02
JP2002532082A (ja) 2002-10-02
DE69936315T2 (de) 2008-02-14
AU773278B2 (en) 2004-05-20
KR100664626B1 (ko) 2007-01-04
CN1187370C (zh) 2005-02-02
HK1041268A1 (en) 2002-07-05
CA2354422A1 (en) 2000-06-22
CN1334819A (zh) 2002-02-06
WO2000035939A2 (en) 2000-06-22
PT1140969E (pt) 2007-08-30
CY1108860T1 (el) 2014-07-02
EP1140969B1 (de) 2007-06-13
CN1334820A (zh) 2002-02-06
CN1170849C (zh) 2004-10-13
KR100664625B1 (ko) 2007-01-04
DE69938507D1 (en) 2008-05-21
EP1140969A4 (de) 2003-07-23
US20100190838A1 (en) 2010-07-29
DE69936315D1 (de) 2007-07-26
EP1140969A1 (de) 2001-10-10
EP1140964A2 (de) 2001-10-10
KR20010101194A (ko) 2001-11-14
AU2181900A (en) 2000-07-03
DK1140969T3 (da) 2007-09-17
EP1140964B1 (de) 2008-04-09
WO2000035936A1 (en) 2000-06-22
CN1660911A (zh) 2005-08-31
AU2004205171A1 (en) 2004-09-16
DE69938507T2 (de) 2009-06-10
AU3121100A (en) 2000-07-03
CA2354456A1 (en) 2000-06-22
MXPA01005949A (es) 2002-09-18
JP4634614B2 (ja) 2011-02-16
US6492129B1 (en) 2002-12-10

Similar Documents

Publication Publication Date Title
ATE364617T1 (de) Fragmente des wachstumsfaktors für bindegewebe (ctgf) und verfahren und anwendungen davon
ATE333888T1 (de) Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
ES2165878T3 (es) Utilizacion del modafinil para el tratamiento de las apneas del sueño y trastornos de ventilacion de origen central.
HUP9603484A2 (hu) Gyógyászati készítmények és eljárás ingerületátvitel befolyásolására
DE693928T1 (de) Aminozucker- und glykosaminoglykanzusammensetzung zur behandlung und reparatus von bindegewebe
DE69632313D1 (de) Desorbierbare extrazelluläre matrix für rekonstruktion eines knorpelgewebes
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE60331546D1 (de) Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung
BR0015698A (pt) Composições e métodos para tratamento de doenças alérgicas
EP0832100A4 (de) Neuartige metalloprotease-inhibitoren, diese enthaltende pharmazeutische zusammensetzungen und anwendungsverfahren
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE526980T1 (de) Zusammensetzungen und verfahren zur heilung von nervengeweben
DE60135364D1 (de) Verwendung von beta-carotin und lycopin zur behandlung des hautalterns durch inhibierung der auswirkung der metalloproteinase des typs 1 der extrazellularen matrix
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE285794T1 (de) Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
RU95105983A (ru) Ингибиторы тромбина, способы их получения и фармацевтическая композиция на их основе
TR200200278T2 (tr) Kalsilitik bileşimler
DE69917317D1 (de) Zubereitung und verwendung von rar antagonisten zur forderung der chondrogenese
ATE222901T1 (de) Carboxylsubstituierte chromanderivate zur verwendung als beta 3 adrenorezeptor-agonisten
ATE546154T1 (de) Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung
ATE498397T1 (de) Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140969

Country of ref document: EP